Psychotherapeutic Text Messaging for Depression Pilot Study

Status Completed

Clinical Trial Summary

Major depression is the leading cause of disability in the United States and is a major contributor to suicide, a leading cause of premature death. The majority of individuals with depression do not receive adequate pharmacologic or psychotherapeutic treatment due to difficulty accessing services or stopping treatment due to side effects, non-response, or the stigma associated with attending mental health clinic visits. Mobile health information technology services, such as text messaging, have the potential to provide effective self-management support for depression to nearly every adult in the US with depression. Guided self-help via text messaging has been shown to be effective for improving a range of health behaviors as well as symptoms of depression. However, previously studied depression text messaging services have not utilized the breadth of psychotherapeutic techniques shown to be effective for depression nor have they attempted to tailor the psychotherapeutic content to the individual in order to improve acceptability and outcomes. Advanced artificial intelligence methods (e.g., reinforcement learning) offers the capability to weed out ineffective messages and to target messages to individuals in order to substantially improve program effectiveness. This pilot study is the first step in towards developing an artificially intelligent text message service for depression.

The specific aims of the study are to: 1) demonstrate the feasibility of recruiting and enrolling participants from the general population of US adults and delivering a text-messaging intervention for depression, 2) determine whether there are differences in the perceived helpfulness of messages derived from different psychotherapeutic treatment modalities, and whether these differences are moderated by participant characteristics (e.g., age, gender, depression symptom severity), 3) determine whether messages derived from different psychotherapeutic treatment modalities or their perceived helpfulness are associated with changes in depression symptoms, and whether these relationships are moderated by participant characteristics.

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02872454
Study type	Interventional
Source	University of Michigan
Contact
Status	Completed
Phase	N/A
Start date	April 2015
Completion date	April 2016

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03062150` - Mineralocorticoid Receptor, NMDA Receptor and Cognitive Function in Depression	N/A
Completed	`NCT04352101` - Bupropion Versus Escitalopram on Reward Circuitry and Motivational Deficits	Phase 4
Completed	`NCT02855918` - Blood Biomarkers in Suicidal Behaviour	N/A
Recruiting	`NCT03039387` - Effects of tDCS on Cognitive Control and Emotion Regulation in Depressed Patients	N/A
Recruiting	`NCT02213016` - Effectiveness of Repetitive Transcranial Magnetic Stimulation in Depressed Patients	Phase 4
Completed	`NCT01683539` - Understanding How Cognitive Remediation Works	N/A
Completed	`NCT01636791` - CBT Versus a Return to Work Intervention for Patients With Common Mental Illness in Primary Care	Phase 3
Recruiting	`NCT02237937` - Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 Gene	Phase 4
Completed	`NCT01201148` - Open Pilot Trial of TES for Depression	Phase 2
Completed	`NCT00953108` - Quetiapine Prolong, Escitalopram and Hypothalamic-pituitary-adrenocortical (HPA) Axis Activity in Depressed Patients	Phase 3
Completed	`NCT00806143` - Bilateral Versus Monolateral Repetitive Transcranial Stimulation in Depression	Phase 4
Terminated	`NCT00695552` - The Effect of Exercise on Depressive Symptoms in Unmedicated Patients	N/A
Completed	`NCT00711737` - Study of the Changes in Metabolic Parameters in Patients Treated With Escitalopram for Six Months	N/A
Terminated	`NCT01244711` - Open-Label Pilot Study to Examine the Value of Substituting Quetiapine for Benzodiazepines	Phase 4
Completed	`NCT00482482` - Yoga in Unipolar and Bipolar Disorders	N/A
Completed	`NCT00466323` - The Effectiveness of FMPO in Improving the Quality of Care for Persons With Severe Mental Illness.	N/A
Completed	`NCT00532480` - Study of Brain Response to Emotional Pictures Using a fMRI While on Duloxetine	Phase 4
Completed	`NCT00616759` - The Effect on Cognition of Terminating ECT Induced Seizures With Propofol	N/A
Recruiting	`NCT00209807` - Effect of Escitalopram vs. Reboxetine on Gastro-intestinal Sensitivity of Patients With Major Depressive Disorder	Phase 4
Completed	`NCT00149110` - Chronos: the Use of Chronobiological Treatment in Depression	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Psychotherapeutic Text Messaging for Depression Pilot Study — TEXT4U

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms